Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Patent
1993-07-16
1997-09-30
Walsh, Stephen
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
530399, 530402, 435697, 536 234, C07K 1400, C07K 14475
Patent
active
056726830
ABSTRACT:
The present invention pertains to a method for delivering a neuropharmaceutical agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of a ligand-neuropharmaceutical agent fusion protein wherein the ligand is reactive with a brain capillary endothelial cell receptor. Other aspects of this invention include a delivery system comprising a ligand reactive with a brain capillary endothelial cell receptor which has formed a fusion protein with a neuropharmaceutical agent. The fusion proteins are also aspects of this invention.
REFERENCES:
patent: 4292425 (1981-09-01), Buckler et al.
patent: 4434156 (1984-02-01), Trowbridge
patent: 4444744 (1984-04-01), Goldenberg
patent: 4545985 (1985-10-01), Pastan et al.
patent: 4569789 (1986-02-01), Blattler et al.
patent: 4626507 (1986-12-01), Trowbridge et al.
patent: 4631190 (1986-12-01), Shen et al.
patent: 4801575 (1989-01-01), Pardridge
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4886780 (1989-12-01), Faulk
patent: 4892827 (1990-01-01), Pastan et al.
patent: 4902505 (1990-02-01), Pardridge
patent: 4992255 (1991-02-01), Pardridge
patent: 5004697 (1991-04-01), Pardridge
patent: 5026651 (1991-06-01), Bowman et al.
patent: 5028697 (1991-07-01), Johnson et al.
patent: 5087616 (1992-02-01), Meyers et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5108987 (1992-04-01), Faulk
patent: 5130129 (1992-07-01), Pardridge
patent: 5132405 (1992-07-01), Huston et al.
patent: 5141736 (1992-08-01), Iwasa et al.
patent: 5169764 (1992-12-01), Shooter et al.
Villa-Komaroff et al., PNAS, vol. 75, pp. 3727-3731, 1978.
Granholm et al., Society for Neurosciences, Abstracts, vol. 18, Part 1, p. 416, No. 183.10, 1992.
Walus et al., J. Cell Biochem Suppl. 15 (Part E) p. 139, N411, 1991.
Kurschner et al., J. of Biol. Chem., vol. 267, pp. 9354-9360, 1992.
Trowbridge, I.S. et al., "Anti-Transferrin Receptor Monoclonal Antibody and Toxin-Antibody Conjugates Affect Growth of Human Tumour Cells", Nature, 294(12): 171-173 (Nov. 1981).
Domingo, D.L. et al., "Transferrin Receptor as a Target for Antibody-Drug Conjugates", Methods in Enzymology, 112: 238-247 (1985).
Zovickian, J. et al., "Potent and Specific Killing of Human Malignant Brain Tumor Cells by an Anti-Transferrin Receptor Antibody-Ricin Immunotoxin", N. Neurosurg., 66: 850-861 (1987).
Jeffries, W.A. et al., "Transferrin Receptor on Endothelium of Brain Capillaries", Nature, 312(8): 162-163 (1984).
Raso, V. et al., "Monensin is Obligatory for the Cytotoxic Action of a Disulfide Linked Methotrexate-Anti-Transferrin Receptor Conjugate", Biochem. Biophys. Res. Comm., 150(1): 104-110 (1988).
Bjorn, M.J. et al., "Immunotoxins to the Murine Transferrin Receptor: Intracavitary Therapy of Mice Bearing Syngeneic Peritoneal Tumors", Cancer Research 47(24, pt. 1): 6639-6645 (Dec. 15, 1971).
Smyth, M.J. et al., "The Mode of Action of Methotrexate-Monoclonal Antibody Conjugates" Immunol. Cell. Biol., 65(2): 189-200 (1987).
Pardridge, W.M. "Receptor-Mediated Peptide Transport through the Blood-Brain Barrier", Endocrine Reviews, 7(3): 314-330 (1986).
Sutherland, R. et al., "Ubiquitous Cell-Surface Glycoprotein on Tumor Cells is Proliferation-Associated Receptor for Transferrin", Proc. Nat'l Acad. Sci. USA, 78(7): 4515-4519 (Jul. 1981).
Shen, W.-C. et al., "CIS-Aconityl Spacer Between Daunomycin and Macromolecular Carriers: A Model of Ph-Sensitive Linkage Releasing Drug from a Lysosomotropic Conjugate" Biochem. and Biophys. Res. Comm. 2(3): 1048-1054 (Oct. 15, 1981).
Pietersz, G.A. et al., "Novel Synthesis and in vivo Characterization of Disulfide-linked Ricin-Monoclonal Antibody Conjugates Devoid of Galactose Binding Activity" Cancer Res., 48: 4469-4476 (1988).
Pietersz, G.A. et al., "The Use of Monoclonal Antibody Conjugates for the Diagnosis and Treatment of Cancer" Immunol. Cell Biol., 65(pt. 2): 111-125 (1987).
Gascoigne, N.R.J. et al., "Secretion of a Chimeric T-Cell Receptor-Immunoglobulin Protein" Proc. Nat'l Acad. Sci. USA 84: 2936-2940 (1987).
Baldwin, R.W. et al., "Monoclonal Antibodies for Radioimmunodetection of Tumours and for Targeting" Bull. Cancer (Paris) 70(2): 132-136 (1983).
Byrn, R.A. et al., "Biological Properties of a CD4 Immunoadhesin" Nature 344: 667-670 (1990).
Griffin, T.W. et al., "In Vitro Cytotoxicity of Recombinant Ricin a Chain-Antitransferrin Receptor Immunotoxin Against Human Adenocarcinomas of Colon and Pancreas" J. Biol. Res. Mod., 7: 559-567 (1988).
Alkan, S.S. et al., "Antiviral and Antiproliferative Effects of Interferons Delivered via Monoclonal Antibodies" J. Interferon Res., 4(3): 355-363 (1984).
Capon, D.J. et al., "Designing CD4 Immunoadhesins for AIDS Therapy" Nature 337: 525-531 (1989).
Dautry-Varsat, A. et al., "pH and the Recycling of Transferrin During Receptor-Mediated Endocytosis" Proc. Nat'l Acad. Sci. USA 80: 2258-2262 (Apr. 1983).
Herz, J. et al., "Low Density Lipoprotein Receptor-related Protein Mediates Endocytosis of Monoclonal Antibodies in Cultured Cells and Rabbit Liver" J. Biol. Chem. 265(34): 21355-21362.
Fishman, J.B. et al., "Receptor-Mediated Transcytosis of Transferrin Across the Blood-Brain Barrier" J. Neur. Res., 18: 299-304 (1987).
Pardridge, W.M. et al., "Selective Transport of an Anti-transferrin Receptor Antibody through the Blood-Brain Barrier in vivo" J. Pharmacol. and Exp. Therapeutics 259(1): 66-70 (1991).
Morrison, S.L. et al., "Genetically Engineered Antibody Molecules: New Tools for Cancer Therapy" Cancer Investigation 6(2): 185-192 (1988).
Dangl, J.L et al., "Segmented Flexibility and Complement Fixation of Genetically Engineered Chimeric Human, Rabbit and Mouse Antibodies," Embo J., 7: 1989-1994 (pub. 1988).
Hoogenboom, H.R. et al., "Cloning and Expression of a Chimeric Antibody Directed Against the Human Transferrin Receptor," J. Immunol. 144(8): 3211-3217 (Apr. 15, 1990).
Batra, J.K. et al., "Antitumor Activity in Mice of an Immunotoxin Made with Anti-Transferrin Receptor and a Recombinant Form of Pseudomonas Exotoxin" Proc. Natl. Acad. Sci. USA, 86: 8545-8549 (Nov. 1989).
Batra, J.K. et al., "Single-Chain Immunotoxins Directed at the Human Transferrin Receptor Containing Pseudomonas Exotoxin A or Diphtheria Toxin: Anti-TFR(Fv)-PE40 and DT388-Anti-TFR(Fv)" Molecular & Cellular Biology 11(4): 2200-2205 (Apr. 1991).
Weber, J.A. and R.A. Weiss, "HIV Infection: The Cellular Picture," In: The Science of AIDS; Readings from Scientific American Magazine, W.H. Freeman and Company, NY, pp. 75-84 (Oct. 1988).
Fingl, E. and D.M. Woodbury, (1975), Section I, Introduction; Chapter I, Principles, In: The Pharmacological Basis of Therapeutics, Goodman et al., Eds. (Macmillan Publishing Co., Inc.) pp. 1-45 (1975).
Pardridge, W.M. et al., "Human Blood-Brain Barrier Transferrin Receptor," Metabolism 36(9): 862-895 (Sep. 1987).
T.A. Waldmann, "Monoclonal Antibodies in Diagnosis and Therapy," Science 252: 1657-1662 (Jun. 21, 1991).
Cumber, A.J. et al., "Preparation of Antibody-Toxin Conjugates," Methods in Enzymology 112: Academic Press, pp. 207-225 (1985).
Julian, R. et al., "A New Reagent Which May Be Used to Introduce Sulfhydryl Groups into Proteins, and Its Use in the Preparation of Conjugates for Immunoassay," Analytical Biochemistry 132: 68-73 (1983).
The Merck Index, Ninth Edition, (M. Windholz, eds.) No. 9261, "Transferrins," p. 1230 (1976).
Grob, P.M. et al., "Affinity Labeling and Partial Purification of Nerve Growth Factor Receptors from Rat Pheochromocytoma and Human Melanoma Cells," Proc. Natl. Acad. Sci. USA 80: 6819-6823 (Nov. 1983).
Flanagan, P.A. et al., "Evaluation of Protein-N-(2-hydroxypropyl)methacrylamide Copolymer Conjugates as Targetable Drug Carriers . . . " Biochimica et Biophysica Acta 993: 83-91 (1989).
H.R. Hoogenboom et al., "Construction and Expression of Antibody-Tumor Necrosis Factor Fusion Proteins," Mol. Immun. 28(9): 1027-1037 (1991).
S.M. Rybak et al., "Humanization of Immunotoxins" Proc. Natl. Acad. Sci. USA 89: 3165-3169 (Apr. 1992).
M. Cazzola et al., "Cytotoxic Activity of an Anti-Transferrin Receptor Immunotoxin on Normal a
Friden Phillip M.
Morrison Sherie L.
Park Eun-Chung
Starzyk Ruth M.
Alkermes, Inc.
Teng Sally P.
The Regents of the University of California
Walsh Stephen
LandOfFree
Transferrin neuropharmaceutical agent fusion protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transferrin neuropharmaceutical agent fusion protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transferrin neuropharmaceutical agent fusion protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2257299